---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-088952"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:54:02.479082+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Q2 net loss $73.5M ($0.39/sh), NDA for acoramidis filed with PDUFA Nov 29

## Summary
- Net loss $73.5M ($0.39/sh) vs $157.9M loss a year ago; Q2 revenue $2.2M, H1 revenue $213.3M from Bayer and Kyowa Kirin deals.
- Acoramidis NDA for ATTR-CM accepted; PDUFA date Nov 29, 2024; 42% reduction in composite CVH and ACM events at Month 30.
- Cash, equivalents, marketable securities and short-term restricted cash $587.2M as of June 30, up from $392.6M at Dec 31, 2023.
- Phase 3 FORTIFY study (BBP-418 for LGMD2I/R9) surpassed interim analysis enrollment target; top-line data expected 2025.
- Infigratinib in achondroplasia: +2.50 cm/yr annualized height velocity at Month 18 (p=0.0015), significant body proportionality improvement.

## SEC filing metadata
- accession: 0000950170-24-088952
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000095017024088952/0000950170-24-088952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000095017024088952/bbio-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-088952
- JSON: https://secwatch.observer/filing/0000950170-24-088952.json
- Plain text: https://secwatch.observer/filing/0000950170-24-088952.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.